Kalshi Eyes 24/7 Leveraged Bets on TSLA, NVDA and AAPL With New Perpetual Futures Push: Report
Prediction market platform Kalshi reportedly seeks U.S. approval for 60 stock and ETF perpetual futures, including Tesla, Apple and Nvidia.
Stocks · News reference
Trump's Surgeon General Pick Has Tobacco, Cola Stocks In Portfolio Even as Robert Kennedy Jr. Wages War On Sugary Drinks, Processed Food
President Trump's Surgeon General nominee Dr. Nicole Saphier disclosed investments in Philip Morris and other companies, agreeing to divest if confirmed.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
In-Depth Analysis: Apple Versus Competitors In Technology Hardware, Storage & Peripherals Industry
In the dynamic and cutthroat world of business, conducting thorough company analysis is essential for investors and industry experts. In this article, we will undertake a comprehensive industry comparison, evaluating
Apple Watch Is Winning in a Shrinking Market
Counterpoint expects an Apple Watch upgrade cycle as Series 12 & Ultra 4 launch with new health features and unchanged prices.
Gavin Newsom Takes the Fight to Big Tech With New Curbs on Social Media, AI Use to Protect Kids: ‘Unregulated Technology Puts Our Children at Risk’
California Governor Gavin Newsom signed laws limiting addictive social media features, strengthening AI chatbot safeguards.
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH
Vanguard's VHT and State Street's XPH offer different approaches to healthcare investing. VHT provides broad sector exposure with lower costs (0.09% expense ratio) and higher dividend yield (1.5%), making it ideal for long-term investors. XPH focuses on pharmaceuticals with higher volatility but stronger 1-year returns (57.2% vs 29.3%), appealing to growth-oriented investors willing to accept greater risk.
AbbVie Drug Shows Significant Reductions in Menstrual Migraine Days
AbbVie reported positive Phase 3 LUNA study results for atogepant, proving its efficacy and safety in preventing menstrual migraines.